The bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to issue regulations that establish standardized patient medication information (PMI) in printed form for all prescription drugs covered by 21 U.S.C. 353(b)(1). It mandates FDA rules on authorship, content, format, color, printing, dissemination, and requires manufacturers to develop PMI as part of the drug approval process.
This is important because it converts a voluntary, varied mix of paper and electronic drug information into a single, government‑approved paper format intended to reach patients who lack reliable digital access, and it creates a new misbranding ground for failure to supply the required PMI. The change affects manufacturers, pharmacies, and FDA review resources and raises questions about feasibility, cost, and how the agency will measure the required link between the PMI format and improved health outcomes.
At a Glance
What It Does
The bill requires the Secretary of HHS (via FDA) to issue final regulations within one year specifying the patient medication information that must accompany every prescription drug fill, including content, design, printing, and dissemination standards. It requires manufacturers to develop the PMI and obtain FDA approval as part of the drug application and requires printed delivery with each dispensed prescription.
Who It Affects
Pharmaceutical manufacturers (brand and generic) that submit FDA applications, pharmacies and dispensers that must ensure a printed PMI accompanies each prescription, and FDA reviewers charged with approving and updating PMI. Patients without reliable electronic access and clinicians who counsel patients will also be directly affected.
Why It Matters
The bill standardizes what patients receive across products, which could reduce adverse drug events and align labeling with patient‑centred design—but it imposes production and regulatory burdens, a tight 1‑year rulemaking deadline, and an evidentiary test tying PMI changes to measurable adherence and outcome improvements.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new section (505H) into the FD&C Act directing FDA to adopt regulations that define exactly what must appear in the patient medication information (PMI) that accompanies prescription drugs. FDA must address who authors the PMI, what information it contains, and the physical and visual presentation — including minimum font size, color, graphics, and a requirement that PMI be printed on paper using processes consistent with Current Good Manufacturing Practice (CGMP).
The statute gives FDA one year from enactment to issue final rules.
Under the bill, manufacturers seeking approval for a drug must develop the PMI and submit it for FDA approval as part of their application. The statute lists required content elements the PMI must include — everything from the drug’s established or proper name and national drug code to approved indications, directions, contraindications and warnings, common and serious adverse reactions, risk‑mitigating measures patients can take, when to contact a clinician, storage and disposal guidance, clinically important interactions, statements about data availability for specific subpopulations, the manufacturer’s name and toll‑free number, and a current link to FDA’s consumer adverse event form (Form FDA 3500B or successor).The bill requires FDA’s rulemaking to ensure PMI remains timely and consistent across similar products: rules must create a process for prompt review and updates as new information becomes available, allow harmonized updates across drug classes to reduce confusion, and set specifications developed from documented patient research using actual drug products that demonstrably improve patient learning and understanding.
Importantly, the regulations must be grounded in evidence showing a causal connection between the enhanced PMI and improved medication adherence and medical outcomes. The statute also defines “adequate supply” for PMI in bulk packaging situations and amends Section 502 to make failure to provide PMI as required a misbranding violation, thereby exposing noncompliant products to FDA enforcement under existing misbranding authorities.
The Five Things You Need to Know
FDA must issue final regulations implementing PMI requirements within one year of enactment, covering authorship, content, format, color, printing, and dissemination.
Manufacturers must develop PMI and obtain FDA approval of the PMI as part of their drug application; FDA must approve the PMI before distribution.
The PMI must be supplied in printed paper form with each prescription, produced under processes consistent with Current Good Manufacturing Practice and in an 'adequate supply' for bulk packaging that supplies multiple prescriptions.
Required content includes the drug name and NDC, approved indications, directions, contraindications and warnings, common and serious adverse reactions, mitigation measures, clinically important interactions, subpopulation data statements, manufacturer contact information, and a link to FDA Form 3500B.
Failure to provide PMI as required creates a new misbranding ground under Section 502(hh), subjecting products to FDA misbranding enforcement authorities.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Mandate for FDA rulemaking and 1‑year deadline
This subsection directs the Secretary to issue regulations specifying the PMI required in printed labeling for drugs covered by section 503(b)(1). It explicitly lists topics the rules must cover — authorship, content, format, color, printing, and dissemination — and imposes a firm deadline of one year for final regulations. Practically, that forces FDA to prioritize rule drafting and creates a statutory clock that could compress stakeholder input and internal review.
Manufacturer responsibilities and mandatory content
The bill requires manufacturers applying for a drug approval to develop the PMI and have it approved by FDA as part of their application. It mandates a standardized, non‑promotional plain‑language format with graphics where applicable, a minimum font size and color standards, and printed distribution on paper consistent with CGMP. The statute lists specific mandatory content elements (e.g., NDC, indications, directions, contraindications, adverse reactions, interactions, subpopulation data statements, manufacturer contact, and link to Form 3500B), and requires PMI to accompany each dispensed prescription in adequate supply.
Review, harmonization, research and evidence standards
Subsection (c) requires regulations that enable timely review and updates to PMI as new drugs and information emerge, and allows cross‑product or classwide updates to reduce patient confusion. It also imposes a novel evidence standard: specifications for language, graphics, and format must derive from documented patient research using actual drug products that demonstrate improved patient learning, and the overall change must show a causal link to improved adherence and outcomes. That elevates the regulatory bar for both the design process and FDA’s approval decisions.
Definition of 'adequate supply' for bulk packaging
This short subsection defines 'adequate supply' to mean enough printed PMI to provide one printed copy per prescription when packages contain bulk quantities intended to supply multiple prescriptions. The definition addresses how the printed requirement interacts with multi‑dose or bulk retail packaging, but leaves operational details (e.g., how to track quantities, labeling placement, and distribution logistics) to the implementing regulations.
Makes failure to supply PMI a misbranding violation
The bill adds a new ground (hh) to Section 502 making a drug misbranded if the PMI is not provided in accordance with the new Section 505H. That change ties PMI compliance directly to FDA's existing misbranding enforcement toolbox — including seizure, injunction, and other remedies under the FD&C Act — although it does not create a new penalty schedule in the statute itself. The amendment gives FDA leverage to enforce distribution and labeling compliance once the agency promulgates implementing rules.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients without reliable internet access — they will receive a standardized, approved paper PMI with every prescription, improving access to consistent safety and use information.
- Caregivers and clinicians working with low‑literacy or vulnerable populations — standardized, research‑based formats and graphics may improve comprehension and reduce medication errors during counseling.
- Patient safety advocates and payers — the law is designed to reduce adverse drug events through clearer, uniform patient information, which could lower avoidable ER visits and hospitalizations if the evidence standard is met.
Who Bears the Cost
- Pharmaceutical manufacturers (brand and generic) — they must prepare FDA‑approved PMI for each product, modify labeling and packaging processes to include printed inserts consistent with CGMP, and fund the required patient research demonstrating effectiveness.
- Pharmacies and dispensers — they must ensure a printed PMI accompanies each dispensed prescription, manage inventory of printed inserts (including for bulk packaging), and update workflows to prevent distribution errors.
- FDA and its review staff — the agency must produce final regulations within one year and absorb ongoing review workload to approve PMI, monitor updates, and adjudicate misbranding cases, which could require new resources or reprioritization of existing work.
Key Issues
The Core Tension
The central dilemma is balancing improved, equitable patient access to clear, standardized medication information against the practical, financial, and evidentiary burdens placed on manufacturers, dispensers, and FDA—an approach that could improve safety if the high evidence and research standards are met, but could also delay or complicate access and create compliance risk for smaller market participants.
The bill creates a meaningful tension between universal access and practical implementation. Requiring paper PMI for every prescription addresses digital equity but imposes recurring production, inventory, and distribution costs across manufacturers and pharmacies.
The statutory research and evidence requirements — particularly the mandate that specifications arise from documented patient research using actual drug products and that changes demonstrate a causal connection to improved adherence and outcomes — set a high bar that could delay implementation or favor larger companies with research resources.
Operational ambiguities remain. 'Adequate supply' for bulk packaging is defined only at a high level; the implementing regulations must resolve placement, tracking, and cutoffs for repackagers and dispensers. The one‑year deadline pressures FDA to finalize technical design standards quickly, which could compress stakeholder engagement or force provisional approaches.
Finally, by making noncompliance a misbranding violation, the bill increases enforcement risk; FDA action could ripple into supply chain disruptions if companies or pharmacies fall out of compliance while rules or printing capacity adapt.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.